Citations

Clear

5 citation(s) found for "Smith, Henry G".

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling
Roulstone, Victoria , Kyula, Joan, Appleton, Elizabeth , Bommareddy, Praveen K. , Patrikeev, Anton , Jones, Sylwia , Kuncheria, Linta, Hak, Charleen ML Chan Wah, Foo, Shane Siang Chin, Baldock, Holly , Wongariyapak, Amarin , Leslie, Isla, Pickering, Robert J. , Zierhut, Christian , Smith, Henry G, Mohan, Nitya , Murano, Carmen , Hubbard, Lisa C. , Patin, Emmanuel C. , Gkantalis, Jim, Pedersen, Malin , Layzell, Scott , Mannion, Jonathan , Fernando, Winnie , Meier, Pascal, Vile, Richard, Melcher, Alan , Coffin, Robert S., Harrington, Kevin J. , Foo, Shane , Hak, Charleen Chan Wah , Chan Wah Hak, Charleen Ml , Pickering, Robert , Dean, Isaac , Patin, Emmanuel C , Gkantalis, Jim , Pedersen, Malin , McLaughlin, Martin , Mannion, Jonathan , Melcher, Alan A , Harrington, Kevin , Kyula, Joan , Smith, Henry George , Dean, Isaac , Mansfield, David , McLaughlin, Martin , Goicoechea, Maria , Meier, Pascal , Vile, Richard G.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 3, 2026 | Volume: 14 | Issue: 3 | Pages: e013692

10.1136/jitc-2025-013692 | PMID 41775431 Get It

Background Antitumor immune responses induced by oncolytic immunotherapy (OI) are often followed by upregulation of programmed death-ligand 1 (PD-L1). As such, the combination of OI with blockade of the programmed cell death protein-1 (PD-1)/PD-L1 axis has demonstrated therapeutic activity in preclinical and clinical trials. The purpose of this study is to understand further the immune-mediated mechanism of interaction between oncolytic viruses and anti-PD-1 therapy. Methods Tumor cells and immune cells (splenocytes) were cultured separately, or in co-culture with vusolimogene oderparepvec, an oncolytic herpes simplex virus expressing the fusogenic gibbon-ape leukemia virus-fusogenic membrane glycoprotein protein (GALV) and granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as RP1. Viral replication, interferon (IFN) responses and PD-L1 expression were analyzed using wild-type, IFNAR1, TNFAR1 and STING knockout splenocytes. In vivo studies evaluated immune cell infiltrates into the tumor following RP1 administration with anti-PD-1 therapy. Results RP1 replication was evident in tumor cells but not splenocytes. This was also accompanied by upregulated IFN expression in cultured splenocytes that was absent in cultured tumor cells. However, when these cell types were co-cultured, splenocytes mediated an interferon response to RP1 via STING that was transmitted to tumor cells in a non-touch-dependent manner. Tumor cells responded to these input signals via upregulation of cell surface major histocompatibility complex-I and PD-L1 through tumor intrinsic JAK-STAT signaling. In vivo, an IFN signature was observed following intratumoral injection of RP1, both in injected and non-injected tumors, which was further increased when combined with anti-PD-1 therapy. Marked upregulation of PD-L1 was observed in tumors injected with RP1 accompanied by the recruitment of CD11b+Ly6G+neutrophils into the tumor microenvironment, which stained positive for PD-L1. Conclusion Overall, the data demonstrate that RP1 remodels the tumor microenvironment through a combination of direct and indirect effects on both tumor and immune cells, resulting in an overall more inflamed phenotype.
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy
Nair, Dileep , Laxer, Kenneth D. , Weber, Peter, Murro, Anthony M., Park, Yong D., Barkley, Gregory L., Smith, Brien, Gwinn, Ryder P. , Doherty, Michael J. , Zimmerman, Richard S. , Bergey, Gregory K. , Anderson, William S. , Heck, Christianne, Liu, Charles Y. , Lee, Ricky W. , Sadler, Toni, Duckrow, Robert B., Wharen, Robert E. , Tatum, William O. , Srinivasan, Shraddha, Agostini, Mark, Alexopoulos, Andreas V. , Jobst, Barbara C. , Roberts, David W. , Salanova, Vicenta , Witt, Thomas C., Cash, Sydney S. , Halford, Jonathan J. , Spencer, David , Ernst, Lia , Skidmore, Christopher , Sperling, Michael R. , Miller, Ian , Geller, Eric B., Berg, Michel J., Fessler, A. James, Rutecki, Paul , Mizrahi, Eli M., Shields, Donald C. , Schwartz, Theodore H. , Labar, Douglas, Fountain, Nathan B. , Elias, W. Jeff, Olejniczak, Piotr W., Villemarette-Pittman, Nicole R. , Eisenschenk, Stephan, Roper, Steven N. , Boggs, Jane , Courtney, Tracy A., Sun, Felice T., Seale, Cairn G. , Miller, Kathy L. , Skarpaas, Tara L. , Morrell, Martha J. , Study, on behalf of the RNS System LTT, Meador, Kimford J. , Vossler, David G. , Hays, Ryan , Liow, Kore , Nair, Dileep R, Weber, Peter B, Smith, Brien J, Noe, Katherine H. , McKhann, Guy M. , Agostini, Mark A, Alexopoulos, Andreas V , Edwards, Jonathan C, Spencer, David C, Skidmore, Christopher T., Goldman, Alica M. , Gross, Robert E, Labar, Douglas R, Boggs, Jane G, Sperling, Michael R , Halford, Jonathan J , Fountain, Nathan , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J , Ernst, Lia D , Hirsch, Lawrence J. , Cole, Andrew J. , Worrell, Gregory A. , Lundstrom, Brian N. , Edwards, Jonathan C. W. , Gross, Robert E. , Study, on behalf of the RNS System LTT

Mayo Clinic

Neurology | July 20, 2020 | Volume: 95 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000010154 | PMID 32690786 Get It

Intercontinental collaborative experience with abdominal, retroperitoneal and pelvic schwannomas
Group, Transatlantic Australasian Retroperitoneal Sarcoma Working, Barros, J Monteiro de, Hodson, James , Glasbey, James , Massey, Robert L., Rintoul-Hoad, O, Chetan, M , Desai, A , Gourevitch, David, Ford, Samuel , Hayes, Andrew , Lopez‐Aguiar, Alexandra G. , Johnson, Aileen C. , Swallow, Carol J. , Burtenshaw, Sally M., Weng, R, Purgin, B, Raut, Chandrajit P. , Fairweather, Mark , Novak, Marko , Reid, Fiona , Mullinax, John E. , Coevorden, Frits van , Houdt, Winan J. van , Haas, Rick L. , Boven, Hester van, Heeres, Birthe C. , van Houdt, Winan J , Group, Transatlantic Australasian Retroperitoneal Sarcoma Working, Massey, R, Almond, Max , Strauß, D. , Smith, Henry George , Cardona, Kenneth , Nessim, Carolyn , Gronchi, Alessandro , Fiore, M, Callegaro, Dario , Bagaria, Sanjay P. , Gyorki, David E. , González, Ricardo

Mayo Clinic

Journal of British Surgery | November 18, 2019 | Volume: 107 | Issue: 4 | Pages: 452-463

10.1002/bjs.11376 | PMID 31736066 Get It

Abstract Background Schwannomas are rare tumours that pose a significant management challenge in the abdomen, retroperitoneum and pelvis. No data are available to inform management strategy. Methods A collaborative international cohort study, across specialist sarcoma units, was conducted to include adults presenting between 2000 and 2017 with histopathologically confirmed schwannomas within the abdomen, retroperitoneum or pelvis. Results Of 485 patients across 12 centres, 38 (7·8 per cent) were discharged without follow-up, 199 (41·0 per cent) underwent early resection and 248 (51·1 per cent) had radiological monitoring. Of these 248 patients, 96 (38·7 per cent) eventually had surgery, giving an overall resection rate of 60·8 per cent (295 of 485). At baseline, median tumour volume was 90·1 (i.q.r. 26·5–262·0) cm3. The estimated growth rate was 10·5 (95 per cent c.i. 9·4 to 11·6) per cent per year, and was consistent in the short term (within 2 years of diagnosis) and long term (beyond 2 years) (ρ = 0·405, P = 0·021). A decision to operate was more common in symptomatic patients (P < 0·001) and for rapidly growing tumours (growth rate more than 20 per cent per year) (P = 0·025). R0/R1 resection was achieved in 91·6 per cent of patients (263 of 287). Kaplan–Meier long-term recurrence rates after R0/R1 resection were 2·3 and 6·7 per cent at 3 and 5 years respectively. Conclusion Specific recommendations include: indications for early surgery, prediction of growth from radiological monitoring, promotion of selective submacroscopic resection and cessation of postoperative imaging surveillance.
The Effect of Recording Montage and Tone Burst Duration on Cervical and Ocular Vestibular Evoked Myogenic Potential Latency and Amplitude
Smith, Kaylee , McCaslin, Devin L. , Jacobson, Gary P. , Burkard, Robert, Smith, Kaylee J.

Mayo Clinic

American Journal of Audiology | April 30, 2019 | Volume: 28 | Issue: 2 | Pages: 300-307

10.1044/2018_aja-17-0055 | PMID 31038981 Get It

Objectives The objectives of this study were (a) to investigate the optimal tone burst duration when recording the cervical vestibular evoked myogenic potential (cVEMP) and the ocular vestibular evoked myogenic potential (oVEMP) and (b) to determine whether monopolar recording influences the latency or amplitude of the cVEMP or the oVEMP. Method Fifteen subjects ( M = 27.7 years, SD = 6.73 years) participated in this study. The participants had no prior history of otological or neurological disease. Both oVEMPs and cVEMPs were recorded at a fixed stimulus level for stimulus durations of 2, 5, 10, and 25 ms. For both cVEMP and oVEMP, responses were obtained using a traditional differential recording montage and a monopolar recording montage. Results The cVEMP and the oVEMP had the greatest amplitude in the 2-ms stimulus condition. There was a statistically significant decrease in amplitude for durations greater than 2 ms. Monopolar and bipolar cVEMP and oVEMP latencies and amplitudes were not significantly different. Conclusion As stimulus duration increased beyond 2 ms, the amplitude of the response decreased for both the cVEMP and the oVEMP. There was no significant change in latency with increasing stimulus duration for either response. These results suggested the optimal stimulus duration for both the oVEMP and cVEMP is 2 ms, and there is no apparent advantage of using a bipolar recording technique.
Development of best practice recommendations for the safe use of pulmonary hypertension pharmacotherapies using a modified Delphi method
Smith, Zachary , Rangarajan, Krishna, Barrow, Jennifer , Carter, Danielle, Falvey, Jennifer , Fester, Keith A. , Guido, M. , Hao, Diana, Ou, Narith N., Pogue, Kristen , MacDonald, Nancy, Barrow, Jennifer, Coons, James C , Dzierba, Amy L. , Guido, Maria R

Mayo Clinic

American Journal of Health-System Pharmacy | January 17, 2019 | Volume: 76 | Issue: 3 | Pages: 153-165

10.1093/ajhp/zxy020 | PMID 30689746 Get It